Attached files
file | filename |
---|---|
EX-32 - EX-32 - Theravance Biopharma, Inc. | a2234657zex-32.htm |
EX-31.2 - EX-31.2 - Theravance Biopharma, Inc. | a2234657zex-31_2.htm |
EX-31.1 - EX-31.1 - Theravance Biopharma, Inc. | a2234657zex-31_1.htm |
EX-21.1 - EX-21.1 - Theravance Biopharma, Inc. | a2234657zex-21_1.htm |
10-K - 10-K - Theravance Biopharma, Inc. | a2234657z10-k.htm |
QuickLinks -- Click here to rapidly navigate through this document
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
- (1)
- Registration
Statements (Form S-8 Nos. 333-198206, 333-202856, 333-210225, and 333-216446) pertaining to the Theravance Biopharma, Inc. 2013
Equity Incentive Plan and the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan,
- (2)
- Registration
Statement (Form S-8 No. 333-200225) pertaining to the Theravance Biopharma, Inc. 2014 New Employee Equity Incentive Plan, and
- (3)
- Registration Statement (Form S-3 No. 333-214257) of Theravance Biopharma, Inc.,
of our reports dated February 28, 2018, with respect to the consolidated financial statements of Theravance Biopharma, Inc. and the effectiveness of internal control over financial reporting of Theravance Biopharma, Inc., included in this Annual Report (Form 10-K) for the year ended December, 31, 2017.
/s/ Ernst & Young LLP
San
Jose, California
February 28, 2018
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM